Kalaris Therapeutics, Inc.
KLRS evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for KLRS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · KLRS
Kalaris Therapeutics, Inc. (KLRS) is a clinical-stage biopharmaceutical company developing TH103, a therapeutic candidate for neovascular age-related macular degeneration (nAMD) and other exudative retinal diseases. The company has no approved products or revenue and is currently conducting Phase 1b/2 clinical trials, with preliminary data expected in the second half of 2026.
Key risk: Clinical and regulatory risk
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates for Kalaris Therapeutics, Inc..
Kalaris Therapeutics, Inc. (KLRS) is a clinical-stage biopharmaceutical company developing TH103, a therapeutic candidate for neovascular age-related macular degeneration (nAMD) and other exudative retinal diseases. The company has no approved products or revenue and is currently conducting Phase 1b/2 clinical trials, with preliminary data expected in the second half of 2026.
- Kalaris Therapeutics is focused on developing TH103 for nAMD and other exudative and neovascular retinal diseases [sec · filed 2025-12-17].
- The company is conducting a Phase 1b/2 clinical trial of TH103 in patients with nAMD [sec_mda · as of 2026-03-17].
- As of June 30, 2026, Kalaris reported cash and equivalents of $43.7M, net income of -$11.5M, and shareholders' equity of $53.1M [sec].
- The company has not generated any revenue from product sales and has incurred significant operating losses since inception [sec_mda · as of 2026-03-17].
- Preliminary data from the ongoing Phase 1b/2 study is expected to be shared in the second half of 2026 [sec · filed 2025-12-17].
What works
- Kalaris has a focused pipeline on a single candidate, TH103, for a large market (nAMD) with potential for additional indications [sec · filed 2025-12-17].
- The company has a cash runway supported by $43.7M as of June 30, 2026, which may fund operations through key clinical milestones [sec].
- TH103 is being evaluated in a Phase 1b/2 trial, with preliminary data expected in H2 2026, providing a near-term catalyst [sec · filed 2025-12-17].
What to weigh
- Kalaris has no approved products, no revenue, and a history of significant operating losses, with net income of -$11.5M for the six months ended June 30, 2026 [sec].
- The company will need substantial additional funding to continue operations and advance TH103, as it expects expenses to increase significantly [sec_mda · as of 2026-03-17].
- Clinical development is uncertain; TH103 may never generate necessary data for regulatory approval or achieve commercial success [sec_mda · as of 2026-03-17].
- The company's ability to achieve profitability depends heavily on the successful development and commercialization of TH103, which may never occur [sec_mda · as of 2026-03-17].
From the filings
Quoted directly from source documents.
Kalaris is developing TH103 for nAMD and other retinal diseases.
“the therapeutic potential of TH103 for nAMD and other exudative and neovascular retinal diseases”
SEC filings · December 17, 2025
The company expects to share preliminary Phase 1b/2 data in the second half of 2026.
“share preliminary data from the ongoing Phase 1b/2 study in the second half of 2026”
SEC filings · December 17, 2025
Kalaris has no revenue and significant operating losses.
“Since our inception, we have not generated any revenue from product sales and have incurred significant operating losses and negative cash flows from our operations.”
SEC MD&A · March 17, 2026
The company will need additional funding to continue operations.
“we will need to obtain substantial additional funding in connection with our continuing operations”
SEC MD&A · March 17, 2026
Risks & what to watch (4)›
Key risks
- Clinical and regulatory risk — TH103 may fail in clinical trials or not receive regulatory approval; delays in enrollment or data readouts are possible [sec · filed 2026-03-09].
- Financing risk — The company needs substantial additional capital to fund operations and development; may not secure funding on acceptable terms [sec_mda · as of 2026-03-17].
- Commercialization risk — Even if approved, TH103 may not achieve commercial success or generate sufficient revenue [sec_mda · as of 2026-03-17].
- Single-product dependency — Kalaris relies entirely on TH103; any setback could materially harm the business [sec_mda · as of 2026-03-17].
What to watch
- Preliminary Phase 1b/2 data for TH103 expected in the second half of 2026 [sec · filed 2025-12-17].
- Cash runway and any additional financing activities given $43.7M cash as of June 30, 2026 [sec].
- Updates on regulatory interactions or plans to advance TH103 into Phase 3 trials [sec · filed 2026-07-17].
- Any strategic transactions or partnerships to support development [sec_mda · as of 2025-03-07].
Sources: SEC filings · SEC MD&A · Generated August 17, 2026 · How we verify sources →
Run Kalaris Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Kalaris Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
25.0 months
D/E 0.73 · 0% dilution
Lead: Phase 3
4 candidates
No upcoming catalysts tracked
1 buy · 1 sell (180d)
Runway
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
53
Total value held
$98.1M
| Holder | Shares | Value |
|---|---|---|
| samsara biocapital, llc | 12,948,081 | $74.7M |
| rtw investments, lp | 1,300,000 | $7.5M |
| alyeska investment group, l.p. | 572,687 | $3.3M |
| vanguard capital management llc | 510,696 | $2.9M |
| woodline partners lp | 200,000 | $1.2M |
| raymond james financial inc | 118,887 | $686K |
| goldman sachs group inc | 110,503 | $638K |
| adar1 capital management, llc | 100,000 | $577K |
| whi trust co llc | 97,493 | $563K |
| boothbay fund management, llc | 92,261 | $532K |
Showing top 10 of 53 institutional holders of Kalaris Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 9.4%
- Days to cover
- 10.6
- Shares short
- 842,687
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
KLRS short interestFrequently asked questions
What is the AI investment thesis for Kalaris Therapeutics, Inc.?
Kalaris Therapeutics, Inc. (KLRS) is a clinical-stage biopharmaceutical company developing TH103, a therapeutic candidate for neovascular age-related macular degeneration (nAMD) and other exudative retinal diseases. The company has no approved products or revenue and is currently conducting Phase 1b/2 clinical trials, with preliminary data expected in the second half of 2026.
What is Kalaris Therapeutics, Inc.'s lead drug candidate?
Kalaris Therapeutics, Inc.'s most advanced tracked candidate is alvr106 (Phase 1) for respiratory diseases caused by human metapneumovirus, influenza, parainfluenza virus, and respiratory syncytial virus.
Who is the CEO of Kalaris Therapeutics, Inc.?
Mr. Andrew Oxtoby is the chief executive officer of Kalaris Therapeutics, Inc. (KLRS).
Where is Kalaris Therapeutics, Inc. headquartered?
Kalaris Therapeutics, Inc. (KLRS) is headquartered in Berkeley Heights, NJ, United States.
What therapeutic areas does Kalaris Therapeutics, Inc. focus on?
Kalaris Therapeutics, Inc. develops therapies across Oncology, Ophthalmology, Infectious Disease, Respiratory.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.